Clinical trials: Diabetes, Type 1
Diabetes Type 1, Diabetes Type 2 on Insulin
EkiYou-Study-2 : A National Multicentric Trial of the EkiYou Application for Insulin Bolus Calculation
EkiYou-Study-2 is an interventional multicenter randomised controlled clinical investigation according to EU 2017/745. It is conducted in 154 adults with diabetes and treated by multiple daily insulin injections that will be…
- Conditions
- Diabetes Type 1, Diabetes Type 2 on Insulin, Pancreatogenous Diabetes
- Trial name
- NCT06738849
- Testing
- EkiYou V2
- Where
- 16 sites in France
- Volunteers
- 154 people
- Sponsor
- DiappyMed
Obesity, Diabetes Mellitus, Type 2
A First-In-Human Study of ARO-ALK7 in Adults With Obesity With and Without Type 2 Diabetes Mellitus
This is a Phase 1/2a double-blind dose-escalating study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of ARO-ALK7 in adult participants with obesity without…
- Trial name
- NCT06937203
- Testing
- ARO-ALK7
- Where
- 8 sites in Australia, New Zealand
- Volunteers
- 150 people
- Sponsor
- Arrowhead Pharmaceuticals
Type1 Diabetes Mellitus
21 Day Comparison of Continuous Insulin Infusion Using HDV Insulin to Standard Insulin in Type 1 Diabetes Mellitus
Single Center, Double Blind, Active Comparator Controlled 2-Way Crossover Multiple Dose Safety, Tolerability and Efficacy Study
- Trial name
- NCT03156361
- Testing
- HDV insulin lispro 100 UNIT/mL, Insulin Lispro 100 Units/mL
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Diasome Pharmaceuticals
Diabetes Mellitus, Type 2
Trial to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of BI135585 XX Administered as Tablet and as Solution in Healthy Volunteers
The purpose of the study is to investigate the safety, tolerability, pharmacokinetics incl. dose proportionality, and pharmacodynamics of BI 135585 XX (Part 1), as well as the relative bioavailability of two different immediate…
- Trial name
- NCT01146886
- Testing
- BI 135585
- Where
- Germany
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Type 1 Diabetes
Safety and Effectiveness of the MiniMed™ 780G System With DS5 CGM
The purpose of this study is to confirm the safety and effectiveness of the MiniMed 780G insulin pump used in combination with the DS5 CGM in type 1 diabetes adult and pediatric subjects in a home setting.
- Trial name
- NCT05714059
- Testing
- Insulin Pump with Continuous Glucose Monitoring
- Where
- 23 sites in United States
- Volunteers
- 250 people
- Sponsor
- Medtronic MiniMed, Inc.
Type 2 Diabetes Mellitus
Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Participants With Type 2 Diabetes Mellitus (MK-0431-251)
The primary objectives of this study are to determine if sitagliptin treatment is not inferior to that of glimepiride as measured by the change in baseline hemoglobin A1C (HbA1C) after 30 weeks of treatment, and if sitagliptin…
- Trial name
- NCT01189890
- Testing
- sitagliptin phosphate, Glimepiride
- Volunteers
- 480 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes, Diabetes Mellitus, Type 1
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Explorative Formulation of Insulin Degludec
This trial is conducted in Europe. The aim of this trial is to investigate the safety, tolerability, pharmacokinetics (the exposure of the trial drug in the body) and pharmacodynamics (the effect of the investigated drug on the…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT01865279
- Testing
- insulin degludec, isophane human insulin
- Where
- Germany
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Non-Proliferative Diabetic Retinopathy, Cataract
Nepafenac Once Daily for Macular Edema - Study 1
The purpose of this study is to demonstrate superiority of Nepafenac Ophthalmic Suspension, 0.3% dosed once daily relative to Nepafenac Vehicle based upon clinical outcomes among diabetic subjects following cataract surgery.
- Trial name
- NCT01853072
- Testing
- Nepafenac Ophthalmic Suspension, 0.3%, Nepafenac vehicle, Prednisolone acetate
- Volunteers
- 881 people
- Sponsor
- Alcon Research
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Post-marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Tresiba®
This study is conducted in Asia. The aim of this post marketing surveillance (PMS) is to assess safety and effectiveness of long-term treatment with Tresiba® (insulin degludec) in patients with diabetes mellitus requiring insulin…
- Trial name
- NCT01984372
- Testing
- insulin degludec
- Where
- Japan
- Volunteers
- 6,163 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus, Chronic Kidney Disease
A Study to Learn More About Chronic Kidney Disease (CKD) in Patients With Type 2 Diabetes Mellitus (T2DM)
In this observational study, data from the recent past of patients with type 2 diabetes mellitus and chronic kidney disease will be studied.
- Trial name
- CKD-T2DM (NCT05004428)
- Testing
- No intervention
- Where
- Canada
- Volunteers
- 336,376 people
- Sponsor
- Bayer
Hypoglycemia, Diabetes Mellitus, Type 1
Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Subjects With T1DM
A randomized, double-blind, parallel-group trial to confirm the clinical efficacy and safety of dasiglucagon in the rescue treatment of hypoglycemia in subjects with type 1 diabetes mellitus (T1DM) compared to placebo
- Trial name
- NCT03688711
- Testing
- Dasiglucagon
- Where
- 3 sites in United States
- Volunteers
- 45 people
- Sponsor
- Zealand Pharma
Type 1 Diabetes Mellitus
A Phase 2 Two-Part Study of Oral PS1 in Healthy Volunteers and Adults With Newly Diagnosed Type 1 Diabetes
This study consists of 2 sub-studies, including Part A and Part B. Part A is intended to further characterize the pharmacokinetic (PK) profile of PS1 based on existing single ascending dose (SAD) and multiple ascending dose (MAD)…
- Trial name
- NCT07889505
- Testing
- PS1
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Pharmasaga Co. Ltd.
Type 2 Diabetes Mellitus
A Phase 1 Study of Ertugliflozin in Healthy Male Participants (MK-8835-020)
This study will evaluate the absolute oral bioavailability (F) and fraction absorbed (Fa) of ertugliflozin following oral administration of unlabeled ertugliflozin (MK-8835) and intravenous (IV) and oral administration of…
- Trial name
- NCT02411929
- Testing
- Unlabeled ertugliflozin for oral use, 14^C-labeled ertugliflozin for IV use, 14^C-labeled ertugliflozin for oral use
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Kidney Diseases, Diabetic Nephropathies
First-In-Human Study of GFB-024 in Healthy Overweight and Obese Participants, and Participants With Type 2 Diabetes
GFB-024 is intended for use in patients with kidney disease such as diabetic nephropathy. This study is the first time GFB-024 has been used in humans.
- Conditions
- Kidney Diseases, Diabetic Nephropathies, Diabetes Complications, Diabetes Mellitus
- Trial name
- NCT04880291
- Testing
- GFB-024
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Goldfinch Bio, Inc.
Type 2 Diabetes Mellitus
Single Cohort 4-period Study to Assess Pharmacokinetics of Metformin Alone and in Combination With Ranolazine
The purpose of this study is to evaluate the effect of steady-state ranolazine on the steady state PK of metformin in subjects with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT01546597
- Testing
- Metformin, Ranolazine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Gilead Sciences
Diabetes Mellitus, Type 2
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BI 10773 in Type II Diabetes Patients With Different Degrees of Renal Impairment
Assessment of the effect of normal and impaired kidney function on the pharmacokinetics, pharmacodynamics and safety of BI 10773
- Trial name
- NCT01907113
- Testing
- BI 10773
- Where
- 2 sites in Germany
- Volunteers
- 40 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 1
Evaluation of Accu-Chek DiaPort, a Port System for Continuous Intraperitoneal Insulin Infusion, in Patients With Type I Diabetes
The Accu-Chek DiaPort system enables continuous intraperitoneal insulin infusion (CIPII): that is, infusion of insulin into the peritoneal cavity using an Accu-Chek insulin pump and an infusion set.
- Trial name
- NCT01483352
- Testing
- Accu-Chek DiaPort
- Where
- Germany
- Volunteers
- 12 people
- Sponsor
- Hoffmann-La Roche
Diabetic Kidney Disease, Diabetic Nephropathy
A Study in Participants With Diabetic Kidney Disease
The purpose of this study is to determine if LY2382770 is safe and effective at protecting kidney function in participants with kidney disease due to diabetes.
- Conditions
- Diabetic Kidney Disease, Diabetic Nephropathy, Diabetic Glomerulosclerosis
- Trial name
- NCT01113801
- Testing
- LY2382770
- Where
- 78 sites in United States, Australia and 5 more
- Volunteers
- 417 people
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes
A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes
The purpose of the study is to evaluate the safety, tolerability, and efficacy of VX-264 in participants with type 1 diabetes (T1D).
- Trial name
- NCT05791201
- Testing
- VX-264
- Where
- 16 sites in United States, Canada and 5 more
- Volunteers
- 7 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
it is a Group of Metabolic Diseases in, Which a Person Has High Blood Sugar, Either
Effect of Taurine on Glycemic Control in Type I and Type II Diabetic Patients
Diabetes mellitus (DM) and its vascular complications are the one of the most prevalent diseases in the state of Qatar. It is a multifactorial disease associated with the development of retinopathy, nephropathy, neuropathy…
- Conditions
- it is a Group of Metabolic Diseases in, Which a Person Has High Blood Sugar, Either, Because the Body Does Not Produce Enough Insulin,, or Because Cells do Not Respond to the Insulin That
- Trial name
- NCT01226537
- Testing
- Taurine
- Volunteers
- 20 people
- Sponsor
- Hamad Medical Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.